alfuzosin has been researched along with Impotence in 19 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)." | 9.12 | Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. ( Gonzalez, RR; Kaplan, SA; Te, AE, 2007) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 9.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 7.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "To determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective alpha1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED)." | 7.74 | Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. ( Agrawal, KC; Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Koka, PS; Sikka, SC, 2008) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 7.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "This pilot study was undertaken to assess the efficacy and safety of the alpha(1)-blocker alfuzosin 10mg once daily (OD), the PDE-5 inhibitor sildenafil 25mg OD, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)." | 5.12 | Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. ( Gonzalez, RR; Kaplan, SA; Te, AE, 2007) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 5.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| "alpha(1)-Adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin are first-line agents for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), but are only second-line agents (doxazosin and terazosin only) for the treatment of arterial hypertension." | 4.83 | Effects of alpha(1)-adrenoceptor antagonists on male sexual function. ( de la Rosette, JJ; Michel, MC; van Dijk, MM, 2006) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 3.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "To determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective alpha1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED)." | 3.74 | Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. ( Agrawal, KC; Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Koka, PS; Sikka, SC, 2008) |
| "Functional measurement of cavernosal smooth muscle relaxation in the presence of tadalafil and alfuzosin." | 3.74 | Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. ( Alexandre, L; Behr-Roussel, D; Charles Tremeaux, J; Combes, M; Giuliano, F; Gorny, D; Oger, S, 2008) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 3.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 14 (73.68) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Umul, M | 1 |
| Altay, AB | 1 |
| Bademkiran, F | 1 |
| Turna, B | 1 |
| Semerci, MB | 1 |
| Apaydin, E | 1 |
| Cikili, N | 1 |
| Gur, S | 1 |
| Sikka, SC | 1 |
| Chandra, S | 1 |
| Koka, PS | 1 |
| Agrawal, KC | 1 |
| Kadowitz, PJ | 1 |
| Hellstrom, WJ | 1 |
| Liguori, G | 1 |
| Trombetta, C | 1 |
| De Giorgi, G | 1 |
| Pomara, G | 1 |
| Maio, G | 1 |
| Vecchio, D | 1 |
| Ocello, G | 1 |
| Ollandini, G | 1 |
| Bucci, S | 1 |
| Belgrano, E | 1 |
| Roumeguère, T | 1 |
| Zouaoui Boudjeltia, K | 1 |
| Hauzeur, C | 1 |
| Schulman, C | 1 |
| Vanhaeverbeek, M | 1 |
| Wespes, E | 1 |
| Leungwattanakij, S | 1 |
| Watanachote, D | 1 |
| Noppakulsatit, P | 1 |
| Petchpaibuol, T | 1 |
| Choeypunt, N | 1 |
| Tongbai, T | 1 |
| Wanamkang, T | 1 |
| Lojanapiwat, B | 1 |
| Permpongkosol, S | 2 |
| Tantiwong, A | 1 |
| Pripatnanont, C | 1 |
| Akarasakul, D | 1 |
| Kongwiwatanakul, S | 1 |
| Chotikawanich, E | 1 |
| Krilad-O-Larn, S | 1 |
| Ratana-O-Larn, K | 1 |
| Hwang, TI | 1 |
| Chu, SH | 1 |
| Lin, MS | 1 |
| Chen, CS | 1 |
| Lee, LM | 1 |
| Chang, HC | 1 |
| Yeh, SD | 1 |
| Chen, WH | 1 |
| Chiang, PH | 1 |
| Larson, TR | 1 |
| Palea, S | 1 |
| Barras, M | 1 |
| Roehrborn, CG | 1 |
| Van Kerrebroeck, P | 1 |
| Nordling, J | 1 |
| Michel, MC | 2 |
| Seftel, A | 1 |
| van Dijk, MM | 1 |
| de la Rosette, JJ | 1 |
| O'Leary, MP | 1 |
| Kaplan, SA | 1 |
| Gonzalez, RR | 1 |
| Te, AE | 1 |
| Sciarra, A | 1 |
| Oger, S | 1 |
| Behr-Roussel, D | 1 |
| Gorny, D | 1 |
| Charles Tremeaux, J | 1 |
| Combes, M | 1 |
| Alexandre, L | 1 |
| Giuliano, F | 1 |
| Vallancien, G | 1 |
| Emberton, M | 1 |
| Alcaraz, A | 1 |
| Matzkin, H | 1 |
| van Moorselaar, RJ | 1 |
| Hartung, R | 1 |
| Harving, N | 1 |
| Elhilali, M | 1 |
| Höfner, K | 1 |
| Claes, H | 1 |
| De Reijke, TM | 1 |
| Folkestad, B | 1 |
| Speakman, MJ | 1 |
4 reviews available for alfuzosin and Impotence
| Article | Year |
|---|---|
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inh | 2009 |
Current treatment options for benign prostatic hyperplasia and their impact on sexual function.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Erectile Dysfunction; Finasteride; Human | 2003 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
6 trials available for alfuzosin and Impotence
| Article | Year |
|---|---|
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Carbolines; Drug Therapy, Combination; Ere | 2009 |
Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Erectile Dysfunction; Humans; Male; Midd | 2010 |
Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Peni | 2011 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunct | 2003 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; M | 2007 |
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combinati | 1999 |
9 other studies available for alfuzosin and Impotence
| Article | Year |
|---|---|
The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Autonomic Nervous System; Blood Glucose; Body Mass In | 2014 |
Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blotting, Western; Erectile Dysfunction; Immunohistochemistry | 2008 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male | 2012 |
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Animals; Erectile Dysfunction; Male; Muscle Relaxation; Penile Erectio | 2003 |
Ejaculatory dysfunction and alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Ejaculation; Erectile Dysfunction; Humans; Male; Quinazolines; Sulfona | 2004 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erect | 2007 |
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Carbolines; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2008 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturi | 2008 |